No Data
Express News | BAIYUNSHAN PH: The production base of Guangyao Wanglaoji (Yongding) has been put into operation.
Express News | State Council meeting: Deploy measures to deepen the reform of Pharmaceutical and medical instruments regulatory system to promote high-quality development of the pharmaceutical industry.
BAIYUNSHAN PH (00874.HK): Liu Luan has been nominated as a candidate for the Shareholder representative supervisor.
On December 24, Gelonghui reported that BAIYUNSHAN PH (00874.HK) announced that the Board of Directors received a notification from the company's Board of Supervisors, stating that the chairman of the Board of Supervisors, Cai Ruiyu, resigned from his position as the chairman of the ninth Board of Supervisors and as the shareholder representative supervisor due to work adjustments. On the same day, it was announced that Liu Min was nominated as a candidate for shareholder representative supervisor at the tenth meeting of the ninth Board of Supervisors to be held on December 24, 2024.
Daiichi Daigo Lowers Baiyun Shan (00874.HK) Target Price to $21.4
Morgan Stanley issued a report stating that after BAIYUNSHAN PH (00874.HK) announced its third-quarter results, the bank decided to lower its profit forecast for this year to 2030 by 3% to 7%. The earnings per share forecast for this year through 2026 has been revised down to 2.25 RMB, 1.87 RMB, and 1.96 RMB respectively, while also lowering sales forecasts. The bank has slightly reduced the Target Price for BAIYUNSHAN PH from HKD 21.7 to HKD 21.4, maintaining a "market perform" rating.
Baiyunshan Unit Gets Authorization for Indian Gooseberry Lozenge Production
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
No Data
